| Product details |
Supply Impact Dates |
Further Details |
CONCERTA methylphenidate hydrochloride 18mg modified release tablet bottle AUST R: 93862Active ingredients:
methylphenidate hydrochloride
Dosage form:
Tablet, modified release
Sponsor:
Janssen-Cilag Pty Ltd
Phone:
1800226334
|
From
29 Oct 2024
to
31 Dec 2026
|
Shortage status:
Current
Availability:
Limited Availability
Reason:
Manufacturing
Management action:
Patients are advised to consult their healthcare professional to discuss their options.Unregistered products have been approved for supply under Section 19A. See the website and search for the active ingredient: https://www.tga.gov.au/resources/section-19a-approvals. An updated TGA web statement is available at https://www.tga.gov.au/safety/shortages/information-about-major-medicine-shortages/about-shortage-methylphenidate-hydrochloride-products.
|
CONCERTA methylphenidate hydrochloride 27mg modified release tablet bottle AUST R: 124502Active ingredients:
methylphenidate hydrochloride
Dosage form:
Tablet, modified release
Sponsor:
Janssen-Cilag Pty Ltd
Phone:
1800226334
|
From
19 Dec 2024
to
31 Dec 2026
|
Shortage status:
Current
Availability:
Limited Availability
Reason:
Manufacturing
Management action:
Patients are advised to consult their healthcare professional to discuss their options.Unregistered products have been approved for supply under Section 19A. See the website and search for the active ingredient: https://www.tga.gov.au/resources/section-19a-approvals. An updated TGA web statement is available at https://www.tga.gov.au/safety/shortages/information-about-major-medicine-shortages/about-shortage-methylphenidate-hydrochloride-products.
|
CONCERTA methylphenidate hydrochloride 36mg modified release tablet bottle AUST R: 93863Active ingredients:
methylphenidate hydrochloride
Dosage form:
Tablet, modified release
Sponsor:
Janssen-Cilag Pty Ltd
Phone:
1800226334
|
From
16 Dec 2024
to
31 Dec 2026
|
Shortage status:
Current
Availability:
Limited Availability
Reason:
Manufacturing
Management action:
Patients are advised to consult their healthcare professional to discuss their options.Unregistered products have been approved for supply under Section 19A. See the website and search for the active ingredient: https://www.tga.gov.au/resources/section-19a-approvals. An updated TGA web statement is available at https://www.tga.gov.au/safety/shortages/information-about-major-medicine-shortages/about-shortage-methylphenidate-hydrochloride-products.
|
CONCERTA methylphenidate hydrochloride 54mg modified release tablet bottle AUST R: 93864Active ingredients:
methylphenidate hydrochloride
Dosage form:
Tablet, modified release
Sponsor:
Janssen-Cilag Pty Ltd
Phone:
1800226334
|
From
16 Oct 2024
to
31 Dec 2026
|
Shortage status:
Current
Availability:
Limited Availability
Reason:
Manufacturing
Management action:
Patients are advised to consult their healthcare professional to discuss their options.Unregistered products have been approved for supply under Section 19A. See the website and search for the active ingredient: https://www.tga.gov.au/resources/section-19a-approvals. An updated TGA web statement is available at https://www.tga.gov.au/safety/shortages/information-about-major-medicine-shortages/about-shortage-methylphenidate-hydrochloride-products.
|
METHYLPHENIDATE-TEVA XR methylphenidate hydrochloride 18 mg modified release tablet bottle AUST R: 370912Active ingredients:
methylphenidate hydrochloride
Dosage form:
Tablet, modified release
Sponsor:
Teva Pharma Australia Pty Ltd
Phone:
1800 288 382
|
From
04 Sep 2024
to
31 Dec 2025
|
Shortage status:
Current
Availability:
Limited Availability
Reason:
Unexpected increase in demand due to other sponsors unable to supply
Management action:
Patients are advised to consult their healthcare professional to discuss their options.Unregistered products have been approved for supply under Section 19A. See the website and search for the active ingredient: https://www.tga.gov.au/resources/section-19a-approvals. An updated TGA web statement is available at https://www.tga.gov.au/safety/shortages/information-about-major-medicine-shortages/about-shortage-methylphenidate-hydrochloride-products.
|
METHYLPHENIDATE-TEVA XR methylphenidate hydrochloride 27 mg modified release tablet bottle AUST R: 370911Active ingredients:
methylphenidate hydrochloride
Dosage form:
Tablet, modified release
Sponsor:
Teva Pharma Australia Pty Ltd
Phone:
1800 288 382
|
From
14 Jan 2025
to
31 Dec 2025
|
Shortage status:
Current
Availability:
Limited Availability
Reason:
Unexpected increase in demand due to other sponsors unable to supply
Management action:
Patients are advised to consult their healthcare professional to discuss their options.Unregistered products have been approved for supply under Section 19A. See the website and search for the active ingredient: https://www.tga.gov.au/resources/section-19a-approvals. An updated TGA web statement is available at https://www.tga.gov.au/safety/shortages/information-about-major-medicine-shortages/about-shortage-methylphenidate-hydrochloride-products.
|
METHYLPHENIDATE-TEVA XR methylphenidate hydrochloride 54 mg modified release tablet bottle AUST R: 370899Active ingredients:
methylphenidate hydrochloride
Dosage form:
Tablet, modified release
Sponsor:
Teva Pharma Australia Pty Ltd
Phone:
1800 288 382
|
From
30 Sep 2024
to
31 Dec 2025
|
Shortage status:
Current
Availability:
Limited Availability
Reason:
Unexpected increase in demand due to other sponsors unable to supply
Management action:
Patients are advised to consult their healthcare professional to discuss their options.Unregistered products have been approved for supply under Section 19A. See the website and search for the active ingredient: https://www.tga.gov.au/resources/section-19a-approvals. An updated TGA web statement is available at https://www.tga.gov.au/safety/shortages/information-about-major-medicine-shortages/about-shortage-methylphenidate-hydrochloride-products.
|
RITALIN LA methylphenidate hydrochloride 10 mg modified release capsule bottle AUST R: 160228Active ingredients:
methylphenidate hydrochloride
Dosage form:
Capsule, modified release
Sponsor:
Novartis Pharmaceuticals Australia Pty Ltd
Phone:
0298053555
|
From
24 Apr 2025
to
31 Dec 2025
|
Shortage status:
Current
Availability:
Limited Availability
Reason:
Manufacturing
Management action:
Patients are advised to consult their healthcare professional to discuss their options.Unregistered products have been approved for supply under Section 19A. See the website and search for the active ingredient: https://www.tga.gov.au/resources/section-19a-approvals. An updated TGA web statement is available at https://www.tga.gov.au/safety/shortages/information-about-major-medicine-shortages/about-shortage-methylphenidate-hydrochloride-products
|
RITALIN LA methylphenidate hydrochloride 20mg modified release capsule bottle AUST R: 82957Active ingredients:
methylphenidate hydrochloride
Dosage form:
Capsule, modified release
Sponsor:
Novartis Pharmaceuticals Australia Pty Ltd
Phone:
0298053555
|
From
28 Jul 2025
to
31 Dec 2025
|
Shortage status:
Current
Availability:
Limited Availability
Reason:
Manufacturing
Management action:
Patients are advised to consult their healthcare professional to discuss their options.Unregistered products have been approved for supply under Section 19A. See the website and search for the active ingredient: https://www.tga.gov.au/resources/section-19a-approvals. An updated TGA web statement is available at https://www.tga.gov.au/safety/shortages/information-about-major-medicine-shortages/about-shortage-methylphenidate-hydrochloride-products
|
RITALIN LA methylphenidate hydrochloride 30mg modified release capsule bottle AUST R: 82958Active ingredients:
methylphenidate hydrochloride
Dosage form:
Capsule, modified release
Sponsor:
Novartis Pharmaceuticals Australia Pty Ltd
Phone:
0298053555
|
From
11 Jun 2025
to
31 Dec 2025
|
Shortage status:
Current
Availability:
Limited Availability
Reason:
Manufacturing
Management action:
Patients are advised to consult their healthcare professional to discuss their options.Unregistered products have been approved for supply under Section 19A. See the website and search for the active ingredient: https://www.tga.gov.au/resources/section-19a-approvals. An updated TGA web statement is available at https://www.tga.gov.au/safety/shortages/information-about-major-medicine-shortages/about-shortage-methylphenidate-hydrochloride-products
|
RITALIN LA methylphenidate hydrochloride 40mg modified release capsule bottle AUST R: 82959Active ingredients:
methylphenidate hydrochloride
Dosage form:
Capsule, modified release
Sponsor:
Novartis Pharmaceuticals Australia Pty Ltd
Phone:
0298053555
|
From
29 Apr 2025
to
31 Dec 2025
|
Shortage status:
Current
Availability:
Limited Availability
Reason:
Manufacturing
Management action:
Patients are advised to consult their healthcare professional to discuss their options. Unregistered products have been approved for supply under Section 19A. See the website and search for the active ingredient: https://www.tga.gov.au/resources/section-19a-approvals. An updated TGA web statement is available at https://www.tga.gov.au/safety/shortages/information-about-major-medicine-shortages/about-shortage-methylphenidate-hydrochloride-products
|
RITALIN LA methylphenidate hydrochloride 60mg modified release capsules bottle AUST R: 236251Active ingredients:
methylphenidate hydrochloride
Dosage form:
Capsule, modified release
Sponsor:
Novartis Pharmaceuticals Australia Pty Ltd
Phone:
0298053555
|
From
01 May 2025
to
31 Dec 2025
|
Shortage status:
Current
Availability:
Limited Availability
Reason:
Manufacturing
Management action:
Patients are advised to consult their healthcare professional to discuss their options.Unregistered products have been approved for supply under Section 19A. See the website and search for the active ingredient: https://www.tga.gov.au/resources/section-19a-approvals. An updated TGA web statement is available at https://www.tga.gov.au/safety/shortages/information-about-major-medicine-shortages/about-shortage-methylphenidate-hydrochloride-products
|
RUBIFEN LA methylphenidate hydrochloride 10 mg modified release capsules blister pack AUST R: 362233Active ingredients:
methylphenidate hydrochloride
Dosage form:
Capsule, hard
Sponsor:
AFT Pharmaceuticals Pty Ltd
Phone:
02 94200420
|
From
03 Jun 2025
to
15 Dec 2025
|
Shortage status:
Current
Availability:
Unavailable
Reason:
Unexpected increase in demand due to other sponsors unable to supply
Management action:
Patients are advised to consult their healthcare professional to discuss their options.Unregistered products have been approved for supply under Section 19A. See the website and search for the active ingredient: https://www.tga.gov.au/resources/section-19a-approvals. An updated TGA web statement is available at https://www.tga.gov.au/safety/shortages/information-about-major-medicine-shortages/about-shortage-methylphenidate-hydrochloride-products
|
RUBIFEN LA methylphenidate hydrochloride 20 mg modified release capsules blister pack AUST R: 362231Active ingredients:
methylphenidate hydrochloride
Dosage form:
Capsule, hard
Sponsor:
AFT Pharmaceuticals Pty Ltd
Phone:
02 94200420
|
From
28 Jul 2025
to
25 Aug 2025
|
Shortage status:
Current
Availability:
Limited Availability
Reason:
Unexpected increase in demand due to other sponsors unable to supply
Management action:
Patients are advised to consult their healthcare professional to discuss their options.Unregistered products have been approved for supply under Section 19A. See the website and search for the active ingredient: https://www.tga.gov.au/resources/section-19a-approvals. An updated TGA web statement is available at https://www.tga.gov.au/safety/shortages/information-about-major-medicine-shortages/about-shortage-methylphenidate-hydrochloride-products
|
RUBIFEN LA methylphenidate hydrochloride 30 mg modified release capsules blister pack AUST R: 362232Active ingredients:
methylphenidate hydrochloride
Dosage form:
Capsule, hard
Sponsor:
AFT Pharmaceuticals Pty Ltd
Phone:
02 94200420
|
From
10 Jun 2025
to
15 Dec 2025
|
Shortage status:
Current
Availability:
Unavailable
Reason:
Unexpected increase in demand due to other sponsors unable to supply
Management action:
Patients are advised to consult their healthcare professional to discuss their options.Unregistered products have been approved for supply under Section 19A. See the website and search for the active ingredient: https://www.tga.gov.au/resources/section-19a-approvals. An updated TGA web statement is available at https://www.tga.gov.au/safety/shortages/information-about-major-medicine-shortages/about-shortage-methylphenidate-hydrochloride-products.
|
RUBIFEN LA methylphenidate hydrochloride 40 mg modified release capsules blister pack AUST R: 362230Active ingredients:
methylphenidate hydrochloride
Dosage form:
Capsule, hard
Sponsor:
AFT Pharmaceuticals Pty Ltd
Phone:
02 94200420
|
From
13 May 2025
to
15 Dec 2025
|
Shortage status:
Current
Availability:
Unavailable
Reason:
Unexpected increase in demand due to other sponsors unable to supply
Management action:
Patients are advised to consult their healthcare professional to discuss their options. Unregistered products have been approved for supply under Section 19A. See the website and search for the active ingredient: https://www.tga.gov.au/resources/section-19a-approvals. An updated TGA web statement is available at https://www.tga.gov.au/safety/shortages/information-about-major-medicine-shortages/about-shortage-methylphenidate-hydrochloride-products
|
RUBIFEN LA methylphenidate hydrochloride 60 mg modified release capsules blister pack AUST R: 362234Active ingredients:
methylphenidate hydrochloride
Dosage form:
Capsule, hard
Sponsor:
AFT Pharmaceuticals Pty Ltd
Phone:
02 94200420
|
From
18 Apr 2025
to
15 Dec 2025
|
Shortage status:
Current
Availability:
Unavailable
Reason:
Unexpected increase in demand due to other sponsors unable to supply
Management action:
Patients are advised to consult their healthcare professional to discuss their options.Unregistered products have been approved for supply under Section 19A. See the website and search for the active ingredient: https://www.tga.gov.au/resources/section-19a-approvals. An updated TGA web statement is available at https://www.tga.gov.au/safety/shortages/information-about-major-medicine-shortages/about-shortage-methylphenidate-hydrochloride-products
|
RITALIN 10 methylphenidate hydrochloride 10mg tablet blister pack AUST R: 11052Active ingredients:
methylphenidate hydrochloride
Dosage form:
Tablet, uncoated
Sponsor:
Novartis Pharmaceuticals Australia Pty Ltd
Phone:
0298053555
|
From
21 Sep 2025
to
31 Oct 2025
|
Shortage status:
Anticipated
Availability:
Available
Reason:
Manufacturing
Management action:
The sponsor is working to expedite the next shipment. An alternative brand is available.
|
METHYLPHENIDATE-TEVA XR methylphenidate hydrochloride 36 mg modified release tablet bottle AUST R: 370900Active ingredients:
methylphenidate hydrochloride
Dosage form:
Tablet, modified release
Sponsor:
Teva Pharma Australia Pty Ltd
Phone:
1800 288 382
|
From
14 Jan 2025
to
18 Jul 2025
|
Shortage status:
Resolved
Availability:
Available
Reason:
Unexpected increase in demand due to other sponsors unable to supply
|